Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.

Caumanns JJ, Wisman GBA, Berns K, van der Zee AGJ, de Jong S.

Biochim Biophys Acta. 2018 Jul 16. pii: S0304-419X(18)30091-X. doi: 10.1016/j.bbcan.2018.07.005. [Epub ahead of print] Review.

2.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 May 15. doi: 10.1038/s41388-018-0300-6. [Epub ahead of print]

3.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.

PMID:
29685880
4.

Role of the Cytosolic Loop C2 and the C Terminus of YidC in Ribosome Binding and Insertion Activity.

Geng Y, Kedrov A, Caumanns JJ, Crevenna AH, Lamb DC, Beckmann R, Driessen AJ.

J Biol Chem. 2015 Jul 10;290(28):17250-61. doi: 10.1074/jbc.M115.650309. Epub 2015 May 28.

5.

Elucidating the native architecture of the YidC: ribosome complex.

Kedrov A, Sustarsic M, de Keyzer J, Caumanns JJ, Wu ZC, Driessen AJ.

J Mol Biol. 2013 Nov 15;425(22):4112-24. doi: 10.1016/j.jmb.2013.07.042. Epub 2013 Aug 8.

Supplemental Content

Loading ...
Support Center